Anonymous
Guest
Anonymous
Guest
You've got to be either asleep or just plan dimwitted! The "new" company is controlled by a bunch of money grubbing hedge funds that badly overpaid for their investment in KV/TherRx. Do you really think their focus is on "...get(ting) this drug (Makena?) on the straight and narrow"? With at least two ANDA quasi-generics to Makena on the horizon, and at least one NDA pending for the same formula for a different indication (remember that docs are allowed to "off-label" prescribe), the future for Makena is pretty bad. And, in the midst of all the issues with Makena competition on the horizon, and including the current competition with compounded versions of Makena, the current management focuses on trying, AGAIN, to sue the FDA (they lost last time.... case thrown out).
Management really needs to focus on rebuilding their reputation with OB/Gyn docs.... the current state of that reputation is really bad. Makena is a really important, needed, drug in that it is the only FDA approved 17-hydroxyprogesterone caproate approved to forestall threatened premature delivery, but it's price is outrageous and predatory. If Makena was priced in the $100-200 per injection level, rather than the current $390 (or so, negotiated price), many more clinicians would be using the branded Makena instead of the compounded versions since the 3rd party payers would be reimbursing for Makena at that price over the compounded versions. I'd venture a guess that Makena could achieve a building yearly sales gross revenue of at least $100 to $150 million at the 100-200 level, as compared to the approximately stagnant $90 million that it is probably currently generating. AND, at the lower pricing, the market could build, since KV/TherRx would be rebuilding its piss-poor reputation by acknowledging that its current price is preventing the full use of this important drug. Being contrite does wonders in rebuilding trust and reputation in a free market system since docs/consumers tend to give companies that own up to their past mistakes some degree of forgiveness.
Poster: the issues with Makena are not with "...wise cycle management", but rather with predatory pricing and a management team that lost all sense of focus and rational business sense in the last few years.... and from their action in again pursing legal action against the FDA and other government agencies, and "stonewalling" on the price of Makena, they are again indicating that they have not changed their management focus. Too bad. The market tends to either whip these kinds of management into compliance or puts them out of business.
Wow you are so smart. Hey now that your done babbling on, shut the fuck up and get back to work.